These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23996617)

  • 21. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
    Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
    Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
    Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
    Li S; Zhu L; Yao L; Xia L; Pan L
    BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
    Dai Q; Luo H; Li XP; Huang J; Zhou TJ; Yang ZH
    Mutagenesis; 2015 May; 30(3):441-9. PubMed ID: 25690281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
    Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
    Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer.
    Park JS; Jeon EK; Chun SH; Won HS; Lee A; Hur SY; Lee KH; Bae SN; Yoon SC; Hong SH
    Gynecol Oncol; 2011 Feb; 120(2):275-9. PubMed ID: 21093896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
    Scheil-Bertram S; Tylus-Schaaf P; du Bois A; Harter P; Oppitz M; Ewald-Riegler N; Fisseler-Eckhoff A
    Gynecol Oncol; 2010 Nov; 119(2):325-31. PubMed ID: 20728204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM; Tian C; Reed E
    Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Predictive marker for the efficacy of FOLFOX treatment in colon cancer (TS, ERCC1 etc)].
    Kumamoto K; Ishibashi K; Ishida H
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():494-9. PubMed ID: 22214010
    [No Abstract]   [Full Text] [Related]  

  • 35. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
    Lu X; Xiao S; Jin C; van der Straaten T; Li X
    J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
    Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
    Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
    Baba H; Watanabe M; Okabe H; Miyamoto Y; Sakamoto Y; Baba Y; Iwatsuki M; Chikamoto A; Beppu T
    Br J Cancer; 2012 Dec; 107(12):1950-5. PubMed ID: 23169295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.